Success Metrics

Clinical Success Rate
60.0%

Based on 6 completed trials

Completion Rate
60%(6/10)
Active Trials
2(15%)
Results Posted
100%(6 trials)
Terminated
4(31%)

Phase Distribution

Ph phase_2
7
54%
Ph phase_1
1
8%
Ph phase_3
3
23%

Phase Distribution

1

Early Stage

7

Mid Stage

3

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
1(9.1%)
Phase 2Efficacy & side effects
7(63.6%)
Phase 3Large-scale testing
3(27.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

54.5%

6 of 11 finished

Non-Completion Rate

45.5%

5 ended early

Currently Active

2

trials recruiting

Total Trials

13

all time

Status Distribution
Active(2)
Completed(6)
Terminated(5)

Detailed Status

Completed6
Terminated4
Recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
2
Success Rate
60.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (9.1%)
Phase 27 (63.6%)
Phase 33 (27.3%)

Trials by Status

withdrawn18%
completed646%
recruiting215%
terminated431%

Recent Activity

2 active trials
Showing 5 of 13
completedphase_3

Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts

NCT05369975
completedphase_3

Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx

NCT04935177
recruitingphase_2

Imlifidase Prior to Kidney Transplant in Highly Sensitised Children

NCT05753930
terminatedphase_3

A Study With Imlifidase in Anti-GBM Disease

NCT05679401
terminatedphase_1

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)

NCT06241950
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT05369975Phase 3

Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts

Completed
NCT04935177Phase 3

Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx

Completed
NCT05753930Phase 2

Imlifidase Prior to Kidney Transplant in Highly Sensitised Children

Recruiting
NCT05679401Phase 3

A Study With Imlifidase in Anti-GBM Disease

Terminated
NCT06241950Phase 1

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)

Terminated
NCT05049850Phase 2

A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation

Terminated
NCT04711850

An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR

Terminated
NCT03943589Phase 2

A Study of Imlifidase in Patients With Guillain-Barré Syndrome

Completed
NCT06461546Phase 2

Imlifidase in Living Donor Renal Transplantation Highly Sensitized Recipients

Withdrawn
NCT03611621

A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation

Completed
NCT06518005Phase 2

Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome

Recruiting
NCT03897205Phase 2

An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients

Completed
NCT03157037Phase 2

Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13